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Abstract
Background: Device-associated nosocomial infections (DA-NIs), due to MDR Enterobacteriaceae, are a major threat
to patient safety in ICUs. We investigated on Extended-spectrum β-lactamases (ESBL) producing Enterobacteriaceae
and incidence of integrons in these bacteria isolated from ventilator-associated pneumonia (VAP) and catheter-associated
urinary tract infections (CAUTIs) in 18 governmental hospitals in the north of Iran.
Methods: In this cross-section study, the antibiotic susceptibility test was performed using the MIC method; also,
phenotypically detection of ESBL-producing bacteria was carried out by the double-disk synergy (DDS) test. Presence
of ESBL-related genes and integron Classes 1 and 2 was evaluated by the PCR method.
Results: Out of a total of 205 patients with DA-NIs, Enterobacteriaceae were responsible for (72.68%) of infections.
The most common DA-NIs caused by Enterobacteriaceae were VAP (77.18%), CAUTI (19.46%), and sepsis due to
VAP (3.35%). The most frequently Enterobacteriaceae were; Klebsiella pneumoniae 75 (24; 32% ESBL positive), E. coli
69 (6; 8.69% ESBL positive) and Enterobacter spp. 5 (5; 100% ESBL positive). Distribution of ESBL-related genes was as
follows: bla-SHV (94.3%), bla-CTX (48.6%), bla-VEB (22.9%) and bla-GES (17.14%). The incidence rate of integron class 1
and class 2 was (82.92%) and (2.9%) respectively. Eight types of ESBL-producing bacteria were observed.
Conclusions: Due to the fact that the emergence rate of ESBL Enterobacteriaceae is increasing in DA-NIs, co-incidence
of different types of ESBL genes with integrons in 75–100% of strains in our study is alarming for clinicians and
healthcare safety managers. Therefore, regional and local molecular level estimations of ESBLs that are agents of
DA-NIs are critical for better management of empiric therapy, especially for patients in ICUs.
Background
Device-associated nosocomial infections (DA-NIs), espe-
cially ventilator-associated pneumonia (VAP) and catheter-
associated urinary tract infections (CAUTIs) pose the
greatest threat to patient safety in the ICUs [1–3]. VAP is
the most lethal among the two, however, CAUTIs are the
most common Enterobacteriaceae that have been indicated
as the most common cause of extended-spectrum β-
lactamases (ESBL) producing bacteria in ICUs. These
bacteria have a plethora of resistance mechanisms and
often use multiple mechanisms against the same anti-
biotic or use a single mechanism to affect multiple
antibiotics. Resistance to broad-spectrum cephalosporin
is spreading quickly among Enterobacteriaceae and this
is mostly related to acquisition of ESBL genes. Isolates
that express ESBL phenotypes and hydrolize the beta
lactam antibiotics are often multiple drug resistant (MDR)
[4, 5]. The commonly genes related to the ESBL phenotype
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are sulf-hydryl variable (SHV), cefotaxime-beta lactamases
(CTX), Vietnam extended-spectrum β-lactamase (VEB)
and Guyana Extended-Spectrum ß-lactamases (GES)
genes. Integrons as mobile DNA elements, are capable of
detention and excision of antibiotic-resistant genes. Inte-
grons achieve this by site-specific recombination. The dif-
ferent combinations of gene cassettes can contribute to
the diverse genetic organization of integrons. There are
five different classes of integrons. Class 1 integrons are the
most common type that are present in Enterobacteriaceae.
Class 2 integrons are associated with the Tn7 trans-
poson, whose transposition activity is directed at spe-
cific attachment sites on chromosomes or plasmids.
Many of the antibiotic-resistant genes found in clinical
isolates of Enterobacteriaceae are part of a gene cas-
sette inserted into an integron [6]. Due to the potential
of integrons to capture and collect gene cassettes, it is
likely that incidence of MDR bacteria such as ESBL-
producing Enterobacteriaceae, will become more preva-
lent in the future and integrons will continue to threaten
the usefulness of antibiotics as therapeutic agents [6–8].
ESBL genes can be located on integrons, which may facili-
tate the spread of such genetic elements. To the best of
our knowledge, this study is the first of its kind on ESBL-
producing Enterobacteriaceae and incidence of integrons
in these bacteria isolated from VAP and CAUTI as a
major threat to patient safety in ICU wards, which was
conducted in 18 governmental hospitals of Mazandaran
province (The largest province in the north of Iran in
terms of area and population).
Methods
Study population and DA-NIs definitions
This cross-sectional study was conducted in 18 governmen-
tal hospitals that overall contained 1200 ward beds and 100
intensive care unit beds, in Mazandaran province, located
in the north of Iran, during 2014 and 2015. This study was
approved by the Ethics Committee of Mazandaran
University of Medical Sciences (Code No: 879 Date:
July 9, 2014).
DA-NIs were defined as: Catheter-Associated Urinary
Tract Infection; patient with a urinary catheter that had
fever, dysuria, frequency, flank pain, suprapubic pain,
nausea and vomiting. In addition, the urine culture was
positive for 105 colony forming units per mL or more,
with no more than two microorganisms isolated or, must
have had at least two symptoms such as fever, dysuria,
frequency, flank pain, suprapubic pain, nausea and
vomiting plus pyuria.
Ventilator-Associated Pneumonia; Ventilator-associated
pneumonia was indicated in a mechanically ventilated
patient with a chest radiograph that showed new or pro-
gressive infiltrates, cavitation, consolidation, or pleural ef-
fusion 48 h after hospitalization. The patient must have
had at least one of the following criteria: new onset of
purulent sputum or change in character of sputum;
organism cultured from blood or from a specimen ob-
tained by tracheal aspirate, bronchoalveolar lavage or
bronchial brushing, or biopsy.
Sepsis due to VAP; in patients ventilated more than
72 h, and bacteria separated from positive blood culture
and tracheal tube aspirate positive culture were similar;
while the patients had the symptoms of systemic in-
flammatory response syndrome (SIRS).
For all the patients whom were subject to ventilator
and urinary catheter, certain prevention strategies were
used against VAP and CAUTIs.
The prevention strategies for CAUTIs: insert catheters
just for appropriate indications; leave catheters only as
long as needed; only trained nurses insert and maintain
catheters; hand hygiene; Insert catheters using aseptic
technique and sterile equipment; aseptic insertion, main-
tain a closed drainage system; maintain unobstructed
urine flow.
The prevention strategies for VAP are: elevation of the
head of the bed; oral hygiene care; Prophylaxis interven-
tions for peptic ulcer disease and deep vein thrombosis.
Sampling and microbiological methods
For VAP, a deep tracheal aspirate from the endotracheal
tube was obtained, and for CAUTI, urine was aseptically
aspirated from the sampling port of the urinary catheter
for performing gram stain and culture on selective
media. Sampling was done by the head nurses and the
samples were immediately transported in a transport
medium to the microbiology laboratory. All the samples
were routinely cultured on MacConkey and blood agar
plates. Blood samples were cultured in Blood culture
bottles. Isolates were identified at the species level
using standard biochemical tests and microbiological
methods [9, 10].
Antibiotic susceptibility test
Susceptibility of the clinical isolates to routinely used
antibiotics was determined by the standard broth dilu-
tion (micro dilution) technique. MIC was determined
according to the recommendations of the standard
protocol of CLSI 2010. The antibiotics were purchased
from Sigma chemical company. Antibiotics used in this
study were Amikacin, Ciprofloxacin, Imipenem, Gentami-
cin, Ceftazidime, Tobramycin, Piperacillin-Tazobactam,
Cefepime, Colistin and Co-trimoxazole.
Phenotype detection of extended-spectrum
beta-lactamase (ESBL) producing enterobacteriaceae
ESBL-producing Enterobacteriaceae was detected using
the double-disk synergy (DDS) test [11, 12]. ESBL’s
presence was assayed using the following antibiotic
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disks (MAST, UK): cefotaxime (30 μg), cefotaxime/clavu-
lanic acid (30/10 μg), ceftazidime (30 μg), and ceftazi-
dime/clavulanic acid (30/10 μg). Escherichia coli ATCC
25922 strain served as positive controls.
DNA extraction and detection of ESBL-related genes
Enterobacteriaceae that were phenotypically confirmed
as ESBL, were evaluated for ESBL-related genes. DNA of
ESBL-positive Enterobacteriaceae was extracted using a
commercial gene extraction kit (DNA Zist, Iran) according
to the company’s instructions. ESBL-positive strains were
screened by the PCR method for genes bla CTX, bla VEB,
bla GES, bla SHV and also integrons class 1 and class 2.
The set of primers and PCR amplification conditions are
available in Additional file 1. After performing the PCR re-
action, electrophoresis of PCR products was carried out in
2% agarose gel at 70 voltage for 50 min. Then, results were
evaluated under UV light on the UV Trans illuminator. In
all the experiments, the following reference strains were
used as positive controls: K. pneumoniae 7881 (CTXM), K.
pneumoniae 7881 strain (containing SHV), P. aeruginosa
ATCC 27853 (VEB-1), and K. pneumoniae (GES). E. coli
96 K062 was used as a positive control for classes 1 and 2
integrons. A non-ESBL-producing strain (E. coli ATCC
25922) was used as negative control.
Statistical analysis
Data were analyzed using SPSS software version 16.
Descriptive statistics, Chi- square and Fisher’s exact tests
were used for statistical analysis.
Results
Out of total of 205 hospitalized patients with DA-NIs in
ICU wards of the mentioned hospitals during 2014–2015,
Enterobacteriaceae were responsible of 149 (72.68%) of
DA-NIs. The most frequently found Enterobacteria-
ceae were; Klebsiella pneumoniae 75 (24; 32% ESBL
positive & 51; 68% ESBL negative), E. coli 69 (6; 8.69%
ESBL positive & 63; 91.30% ESBL negative) and Entero-
bacter spp. 5 (5; 100% ESBL positive). The most common
DA-NIs caused by Enterobacteriaceae were VAP (77.18%),
CAUTI (19.46%) and sepsis due to VAP (3.35%).
The demographic feature of patients with DA-NIs
caused by ESBL Enterobacteriaceae was as follows; 27 VAP
patients (15; 55.5% male and 12; 44.4% female) with aver-
age age of 66.5 ± 20.17 years and average duration of
hospitalization in the ICU of 28.37 ± 20.03 days; three
CAUTI patients (1; 33.3% male and 2; 66.6% female) with
average age of 45.66 ± 21.93 years and average duration of
hospitalization in the ICU of 19.33 ± 15.63 days; five pa-
tients of sepsis due to VAP (2;40% male and 3;60% fe-
male) with average age of 60.25 ± 14.79 years and average
duration of hospitalization in the ICU of 10.75 ± 1.89 days.
In total, the distribution of ESBL-related genes was 33
(94.3%) bla-SHV, 17 (48.6%) bla-CTX, 8 (22.9%) bla-
VEB and 6 (17.14%) bla-GES. Figure 1 that is the illus-
tration of agarose gel, shows the strains containing VEB,
SHV, int1 (integron class1), int2 (integron class 2), GES
and CTX genes. The Antibiotic susceptibility pattern of
Enterobacteriaceae containing ESBL-related genes is
shown in detail in Table 1. The rate of antibiotic resistance
among strains containing SHV gene was 27.3–78.8%
whereas the rate of sensitivity was 6.1–48.5%. On the
other hand, Gentamicin and Imipenem had the highest re-
sistance and sensitivity rates respectively. The rate of anti-
biotic resistance among strains containing CTX gene was
41.2–88.2%, whereas the rate of sensitivity was 5.9–35%.
In addition, Gentamicin and Ciprofloxacin had the highest
resistance and sensitivity rates respectively. The rate of
antibiotic resistance among strains containing VEB
gene was 12.5–87%, whereas the rate of sensitivity was
12.5–75% and Ceftazidime and Ciprofloxacin had the
highest resistance and sensitivity rates respectively. The
rate of antibiotic resistance among strains containing
Fig. 1 Agarose gel showing the strains containing, VEB, SHV, int1 (integron class1), int2 (integron class 2), GES and CTX genes
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GES gene was 16.7–83.3% whereas the rate of sensitivity
was 16.7–66.7%. On the other hand, Cefepime and Imipe-
nem had the highest resistance and sensitivity rates re-
spectively. The incidence of integrons class 1 and class 2
was 29 (82.92%) and 1 (2.9%) respectively. Antibiotic sus-
ceptibility pattern of integron-positive Enterobacteriaceae
is shown in Table 2.
The rate of antibiotic resistance among integron class
1 positive strain was 35–85%. The only integron class 2
positive strain was Klebsiella pneumoniae and this
isolate was resistant to all the antibiotics. Eight types of
ESBL genes were seen among the isolates. Coincidence
of each type of ESBL-producing bacteria and integron
class 1 is shown in Table 3. Nine strains contained three
ESBL genes (2 strains had GES, VEB, and SHV, 3 strains
had GES, CTX, and SHV and 4 strains had VEB, CTX,
and SHV). Fourteen strains contained 2 ESBL genes
(10 strains had CTX and SHV, one strain had GES and
SHV and three strains had VEB and SHV). Twelve
strains had only one ESBL gene (11 strains contained
Table 1 Antibiotic susceptibility pattern of Enterobacteriaceae containing ESBL related genes
Klebsiella pneumoniae Enterobacter .spp E.coli
N = 24 N = 5 N = 6
Positive ESBL related genes
SHV CTX VEB GES SHV CTX VEB GES SHV CTX VEB GES
N = 22 N = 14 N = 4 N = 4 N = 5 N = 2 N = 3 N = 1 N = 6 N = 1 N = 1 N = 1
Amikacin R 50 50 25 25 60 100 33 0 66.6 100 100 100
I 27.2 28.5 50 25 40 0 66 100 16.6 0 0 0
S 22.7 21.5 25 50 0 0 0 0 16.6 0 0 0
Ciprofloxacin R 40.9 50 0 25 0 0 0 0 33.3 0 0 100
I 31.8 28.5 50 50 0 0 0 0 - - - -
S 27.2 21.5 50 25 100 100 100 100 66.6 100 100 0
Imipenem R 36.3 50 25 50 0 0 0 0 16.6 0 0 0
I 27.2 28.5 25 25 20 50 33 100 16.6 0 0 100
S 36.3 21.5 50 25 80 50 66 0 66.6 100 100 0
Gentamicin R 81.8 85.7 50 100 80 100 33 0 83.33 100 100 100
I 4.54 0 0 0 20 0 33 100 16.6 0 0 0
S 13.63 14.2 50 0 0 0 33 0 - - - -
Ceftazidime R 72.7 57.14 75 50 60 50 100 100 50 100 100 0
I 27.2 35.7 25 25 40 50 0 0 33.3 0 0 100
S 13.63 7.1 0 25 0 0 0 0 16.6 0 0 0
Tobramycin R 59 64.28 50 25 60 100 33 0 33.3 0 0 100
I 31.8 28.57 50 50 0 0 0 0 16.6 0 100 0
S 9.1 7.1 0 25 40 0 66 100 50 100 0 0
Piperacillin-Tazobactam R 63.6 64.28 50 75 60 0 33 100 16.6 0 0 0
I 31.8 28.57 25 25 0 50 66 0 66.6 100 100 100
S 4.54 7.1 25 0 40 50 0 0 16.6 0 0 0
Cefepime R 72.7 85.71 25 100 60 100 66 100 33.3 0 100 0
I 9.1 7.1 25 0 20 0 0 0 16.6 0 0 100
S 18.18 7.1 50 0 20 0 33 0 50 100 0 0
Colistin R 72.7 71.42 50 25 40 100 33 0 33.3 0 0 100
I 27.2 14.2 25 25 20 0 0 0 16.6 100 0 0
S 13.63 14.2 25 50 40 0 66 100 50 0 100 0
Co-trimoxazole R 81.8 85.71 75 75 80 100 66 0 33.3 0 100 100
I - - - - 0 0 0 0 - - - -
S 18.2 14.2 25 25 20 0 33 100 66.6 100 0 0
R resistant, I intermediate, S sensitive
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SHV and one strain had CTX). Coincidence of isolates
that contained different types of ESBL genes and inte-
gron class 1 was 75–100%, which was statistically sig-
nificant (P > .05).
Discussions
DA-NIs due to MDR bacteria are a serious threat to pa-
tient safety, being among of the most serious causes of
morbidity, mortality and economic burden in developing
countries such as Iran. Various studies have shown that
the DA-NIs are a serious issue in Iran [13–16] But no
studies had specifically addressed and evaluated the
ESBL genes and mobile genetic elements such as
integrons in Enterobacteriaceae as common agents of
DA-NIs patients in Iran. It was found in this study
that ESBL-producing Enterobacteriaceae were causa-
tive agents of 23% of DA-NIs in the region. Rosenthal
et al. surveyed DA-NIs in 55 ICUs of eight developing
countries and found that VAP posed the greatest risk
(41%), followed by CVC-related bloodstream infec-
tions (30%) and CAUTI (29%). On the other hand,
they reported Enterobacteriaceae were agents of about
27% of VAPs and 42% of CAUTIs [16]. In our study,
overall 56% of Enterobacteriaceae were resistant to
Table 2 Antibiotic susceptibility pattern of integron positive Enterobacteriaceae
Klebsiella pneumoniae Enterobacter .spp E.coli
N = 24 N = 5 N = 6
Integron class 1 Integron class 2 Integron class 1 Integron class 2 Integron class 1 Integron class 2
N = 20 N = 1 N = 4 N = 0 N = 6 N = 0
Amikacin R 55 100 75 - 66.6 -
I 25 0 25 16.6
S 20 0 0 16.6
Ciprofloxacin R 45 100 0 - 33.3 -
I 35 0 0 -
S 20 0 100 66.6
Imipenem R 35 0 0 - 16.6 -
I 30 0 25 16.6
S 35 100 75 66.6
Gentamicin R 80 100 75 - 83.3 -
I 5 0 0 16.6
S 15 0 25 -
Ceftazidime R 55 100 50 - 50 -
I 30 0 50 33.3
S 15 0 0 16.6
Tobramycin R 60 0 75 - 33.3 -
I 30 100 0 16.6
S 10 0 25 50
Piperacillin-Tazobactam R 70 100 75 - 16.6 -
I 30 0 25 66.6
S 0 0 0 16.6
Cefepime R 80 100 75 - 33.3 -
I 10 0 25 16.6
S 10 0 0 50
Colistin R 60 0 50 - 33.3 -
I 25 100 25 16.6
S 15 0 25 50
Co-trimoxazole R 85 100 75 - 33.3 -
I - - 0 -
S 15 0 25 66.6
R resistant, I intermediate, S sensitive
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the 3rd generation of cephalosporin, and imipenem was
the most effective antibiotic. Similar to the results of this
study, Rosenthal et al. reported that 51% of Enterobacteri-
aceae isolates were resistant to ceftriaxone [16]. Salomao
et al. reported that in five ICUs in three urban hospitals of
Brazil during a three-year period, VAP rate was 20.9 per
1000 ventilator days, CAUTI rate was 9.6 per 1000 cathe-
ter days, and Enterobacteriaceae were agents of 22.8% of
DA-NIs. Enterobacteriaceae in their study were resistant
to ceftriaxone in 96.7% of the cases and resistance to cef-
tazidime was seen in 79.3% of the cases [17]. Guanche-
Garcell in Cuba determined the incidence rate of DA-NIs
to be 17.0% for VAP, 4.4% for CAUTI and 1% for CVC.
They found that overall 51.7% of all DA-NIs were caused
by Enterobacteriaceae. Escherichia coli was responsible for
VAP and CAUTI for 15.4 and 53.8% of the cases res-
pectively. VAP and CAUTI due to Klebsiella spp. were
23.1 and 15.4% respectively. The rate of VAP caused by
Enterobacteriaceae in the mentioned studies was lower
than the findings of this study.
ESBL Enterobacteriaceae pose unique challenges to in-
fection control professionals and antibacterial-discovery
scientists [18, 19]. In this study, prevalence of ESBL-
related genes was; 94.3% for SHV, 48.6% for CTX,
22.9%for VEB and 17.14% for GES. β-Lactams not only
are extensively used for treatment of common infections,
but also frequently used as prophylaxis before surgery.
Enterobacteriaceae are of clinical importance since they
cause infections, especially in patients that use the de-
vices in ICUs. ESBL-producing Enterobacteriaceae are
often MDR, further limiting the therapeutic options. In
the present study, Co-resistance with fluoroquinolones,
aminoglycosides, trimethoprim, and cephalosporins were
found in average in 33–80% of ESBL bacteria. Knowledge
of the local epidemiology of ESBL DA-NIs in molecular
level is very important. For an immunocompromised pa-
tient, such as patients admitted in ICUs with DA-NIs
caused by ESBL-producing Enterobacteriaceae, admin-
istration of an ineffective antibiotic can be lethal. The
rate of ESBL varies geographically but it is increasing
fast in the region; for example in our previous study
on ESBL-Escherichia coli uropathogens of pediatrics
in 2014, the rate of ESBL genes were SHV (44%),
CTX (28%), VEB (8%), and GES (0%); but in this
study, the rate of these genes were 16.6–100% among
E. coli [20]. In addition, Khorshidi et al. in Kashan
and Khosravi et al. in Ahvaz, reported the rates of bla-
SHV to be about 50%, which is lower than the findings
of this study [21, 22]. The prevalence of ESBL-
producing Enterobacteriaceae in Iran has been reported
in different rates by phenotypic confirmatory test.
For example Behroozi et al., reported that 21% of E.
coli and 12% of K. pneumonia isolates were ESBL pro-
ducers; on the other hand, Feizabadi et al. reported that
72% of K. pneumonia strains isolated from Tehran hos-
pitals were ESBL producers. Also in our previous study
on bacteria isolated from patients with chronic sinusitis,
the rate of ESBL-producing bacteria was 28.75–37.03%
among Enterobacteriaceae [12, 23, 24]. High prevalence
of ESBL-producing Enterobacteriaceae that are agents of
DA-NIS in ICUs, represent the rising problem of anti-
biotic resistance rate in the ICUs, which is caused by
suboptimal infection control in hospitals and new muta-
tions of resistant genes. Transmission of the genes of
ESBL enzymes can occur by horizontal gene transfer.
Integrons, as common genetic mobile elements, are as-
sociated with ESBL genes. In this study, the presence of
class 1 integron varied from 80 to 100% among ESBL-
producing species; also eight types of ESBL-producing
Enterobacteriaceae were found. All these types signifi-
cantly correlate with the incidence of integron class 1
(p ≥ 0.02). Similar to these results, association of certain
beta-lactamase genes with class 1 integrons by location
of bla genes within integron platforms (blaVIM, blaIMP,
blaGES, blaVEB, blaCTX-M-2/-9, and blaCMY) or by
sharing the same plasmid context (blaTEM and blaSHV)
among Enterobacteriaceae, has been previously reported
in several studies [25–28].
Conclusions
The emergence of ESBL Enterobacteriaceae among
DA-NIs is increasing in the Mazandaran province. The
emergence of coincidence of different types of ESBL
genes with integrons in 75–100% of strains is really
dangerous and alarming for clinicians and healthcare
safety managers. Due to the fact that prevalence of
ESBL-producing strains can vary greatly from one
ward to another, and even for a given ward in different
points in time, therefore estimating regional and local
ESBL agents of DA-NIs in molecular level in high-risk
wards, at least once a year, could be useful in clinical
decision-making of empiric therapy, especially for pa-
tients in ICUs.
Table 3 Coincidence of ESBL genes types and integron class 1
among Enterobacteriaceae isolated
ESBL types Number Coincidence with
integron class 1
P value
GES, VEB, SHV 2 (5.71) 2 (100) 0.00
GES, CTX, SHV 3 (8.57) 3 (100) 0.00
VEB, CTX, SHV 4 (11.42) 3 (75) 0.00
CTX, SHV 10 (28.57) 8 (80) 0.01
GES, SHV 1 (2.85) 1 (100) 0.00
VEB, SHV 3 (8.57) 1 (100) 0.00
SHV 11 (31.42) 11 (100) 0.02
CTX 1 (2.85) 1 (100) 0.00
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